Celiac Science Argenx's $2.2 Billion Acquisition: What a Vitiligo Deal Means for Celiac Patients Argenx acquires Forte for $2.2B and its phase 2 vitiligo drug. Here's why this autoimmune deal matters to celiac patients and families. Aug 22, 2026 news treatment pipelineautoimmune comorbiditiespharmaceutical research
